TOLREMO therapeutics AG (“TOLREMO”) is a Swiss biotechnology company that was spun out of ETH Zurich in 2017. Based on cutting-edge science and guided by pioneering real-world medicine, TOLREMO created a broad cancer drug resistance platform that provides a unique entry point into a major clinical problem. In two parallel R&D programs the company develops resistance-breaking add-on therapies that extend the therapeutic benefit of oncogene-targeting cancer drugs (Adaptive Drug Resistance Program) and anti-angiogenic cancer drugs (Hypoxia-Driven Drug Resistance Program). TOLREMO’s unique drug resistance platform has the potential to catalyze a new wave of potent resistance-breaking molecules that will meaningfully extend the lives of patients suffering from cancer. To learn more visit www.tolremo.com.
TOLREMO is headquartered on the ETH Hönggerberg campus in Zurich, Switzerland, where the company is part of a dynamic scientific and entrepreneurial community composed of world-leading academic research laboratories, flourishing life sciences spin-offs and cutting-edge technology platforms. TOLREMO enjoys broad access to state-of-the art ETH infrastructure including laboratory space and an industry standard robotic screening facility.
TOLREMO is headquartered on the ETH Hönggerberg campus in Zurich, Switzerland, where the company is part of a dynamic scientific and entrepreneurial community composed of world-leading academic research laboratories, flourishing life sciences spin-offs and cutting-edge technology platforms. TOLREMO enjoys broad access to state-of-the art ETH infrastructure including laboratory space and an industry standard robotic screening facility.
Location: Switzerland, Basel-Landschaft, Muttenz
Employees: 11-50
Total raised: $50.82M
Founded date: 2017
Investors 2
| Date | Name | Website |
| 06.05.2024 | MK Venture... | mk-vc.com |
| - | VentureLab | venturelab... |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 20.09.2023 | Series A | $39M | - |
| 24.09.2018 | Series A | $9.33M | - |
| 19.09.2017 | - | $2.49M | - |
Mentions in press and media 37
| Date | Title | Description |
| 20.04.2026 | Startups gewinnen Awards im In- und Ausland | Die diesjährige Startup Challenge der ABB zielte auf innovative Jungunternehmen ab, die KI-basierte Lösungen für Energieeffizienz und Netzstabilität entwickeln. Unter den sechs Gewinnern ist mit Forgis auch ein Schweizer Robotik-Startup. S... |
| 02.09.2025 | Regulatory milestones and clinical progress for Swiss biotechs | TOLREMO therapeutics AG, a Swiss biotech startup redefining cancer treatment by targeting non-oncogene addiction, has obtained two Fast Track designations from the U.S. Food and Drug Administration (FDA) for its lead candidate, TT125-802 f... |
| 04.07.2025 | Araris-Team sichert sich den mit 100‘000 Euro dotierten Strüngmann Award | Das Gründerteam von Araris Biotech kann auf eine der erfolgreichsten Biotech-Firmengründungen der Schweiz in den vergangenen Jahren zurückblicken. Das 2019 aus dem Paul-Scherrer-Institut gegründete Spin-off hat eine proprietäre Linker-Payl... |
| 30.05.2025 | Schweizer Biotech-Startups dominieren europäischen Award | Das Komitee des Strüngmann Awards hat diese Woche die diesjährigen Finalistinnen und Finalisten bekanntgegeben. Vergeben wird der mit 100.000 Euro dotierte Preis am 3. Juli. In das Finale geschafft haben es: Dragan Grabulovski | Philipp Sp... |
| 06.05.2024 | Innosuisse funded 45 Start-up innovation projects | With the Start-up innovation project, Innosuisse directly funds high potential science-based projects initiated by Swiss start-ups, giving them a financial boost to propel their market entry. The innovation projects must be based on applic... |
| 28.03.2024 | New additions to startups’ board of directors | Trevor Hawkins joins Resistell’s Board of Directors, bringing 25 years of experience from his leadership roles across research, clinical, and corporate spheres globally. He has held several senior executive roles at Siemens Healthcare, Phi... |
| 30.11.2023 | TOLREMO doses first patient in Phase 1 clinical trial | |
| 21.11.2023 | SEF.WomenAward reveals the finalists | |
| 20.09.2023 | TOLREMO Therapeutics secures USD 39 Million in Series A funding to fight non-genetic cancer drug resistance | TOLREMO Therapeutics secures USD 39 Million in Series A funding to fight non-genetic cancer drug resistance 20.09.2023 11:18, Rita Longobardi linkedIn facebook twitter instagram youtube --> BioMedPartners led the round with participation... |
| 20.09.2023 | TOLREMO therapeutics Completes USD 39 Million Series A Financing Round |
Show more